Phreesia, Inc. (NYSE:PHR – Get Free Report) General Counsel Allison C. Hoffman sold 1,212 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $21.03, for a total value of $25,488.36. Following the completion of the transaction, the general counsel now owns 119,791 shares of the company’s stock, valued at approximately $2,519,204.73. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Phreesia Stock Performance
Shares of PHR opened at $19.80 on Friday. Phreesia, Inc. has a 12 month low of $12.05 and a 12 month high of $29.16. The business’s fifty day simple moving average is $23.30 and its two-hundred day simple moving average is $22.41. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -11.00 and a beta of 0.93.
Phreesia (NYSE:PHR – Get Free Report) last released its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.06. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. The company had revenue of $102.12 million for the quarter, compared to analysts’ expectations of $101.76 million. Research analysts anticipate that Phreesia, Inc. will post -1.23 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several brokerages have commented on PHR. DA Davidson reissued a “buy” rating and set a $32.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. JMP Securities reissued a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research note on Thursday, September 5th. Robert W. Baird raised their target price on shares of Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, September 6th. KeyCorp dropped their price target on Phreesia from $27.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, Truist Financial upped their price target on Phreesia from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $29.42.
Read Our Latest Stock Report on Phreesia
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Articles
- Five stocks we like better than Phreesia
- Health Care Stocks Explained: Why You Might Want to Invest
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How to Most Effectively Use the MarketBeat Earnings Screener
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- 3 Ways To Invest In Coffee, Other Than Drinking It
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.